Search Results

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2 and the Phase III MAVERIC-3 clinical trials

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.

Theralase® Technologies Inc. announced that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators at the Canadian Urological Association Bladder Cancer Forum and the American Urology Association, respectively.